EcoDrugPlus

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSSFOG00015001943
Gene Symbol: DDR2
3 Cross references
204 Possible Orthologues:

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSSFOG00015012278
Gene Symbol: DDR2
3 Cross references
192 Possible Orthologues:

Dopamine Receptor D1

Ensembl ID : ENSSFOG00015017983
Gene Symbol: DRD1
3 Cross references
188 Possible Orthologues:

Dopamine Receptor D2

Ensembl ID : ENSSFOG00015002238
Gene Symbol: DRD2
3 Cross references
207 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSSFOG00015021145
Gene Symbol: DRD4
3 Cross references
244 Possible Orthologues:

Dopamine Receptor D4

Ensembl ID : ENSSFOG00015011928
Gene Symbol: DRD4
3 Cross references
244 Possible Orthologues:

Dual Specificity Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSSFOG00015032068
Gene Symbol: LOC108919814
3 Cross references
212 Possible Orthologues:

Echinoderm Microtubule-Associated Protein-Like 4

Ensembl ID : ENSSFOG00015005144
Gene Symbol: LOC108932634
2 Cross references
210 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSSFOG00015000561
Gene Symbol: ENPP2
3 Cross references
227 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSSFOG00015004691
Gene Symbol: ENPP2
3 Cross references
19 Possible Orthologues:

Egl Nine Homolog 2-Like

Ensembl ID : ENSSFOG00015007263
Gene Symbol: LOC108932430
2 Cross references
191 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSFOG00015008300
Gene Symbol: EGLN1
3 Cross references
217 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).